Hosted on MSN4mon
Maze Therapeutics raises $115m to advance kidney disease candidates
Maze Therapeutics has completed a Series D financing ... Deep Track Capital and Frazier Life Sciences co-led the financing round, with Logos Capital and Janus Henderson Investors also taking ...
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...
ETF Daily News29d
Maze Therapeutics, Inc.’s Quiet Period To Expire on March 12th (NASDAQ:MAZE)
Maze Therapeutics’ (NASDAQ:MAZE – Get Free Report) quiet period will expire on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January ...